EXCITING NEW FINDINGS FROM CLINICAL TRIALS IN THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER

Post-traumatic stress disorder (PTSD) is a prevalent and often difficult to treat psychiatric disorder. Over the last several years, the field has seen a modest uptick in the number of novel treatment interventions showing some promise in the treatment of PTSD. These include novel medication combinations, medication-assisted psychotherapy, neuromodulation as stand-alone or adjunct to psychotherapy and other novel devices, such as electroencephalogram-driven neurofeedback. Despite consumer excitement for stellate ganglion block and hyperbaric oxygen therapy, results from studies are mixed. This update provides a comprehensive review of recent findings from clinical trials and highlight ongoing studies in the treatment of PTSD.

Learning Objective 1: The attendee will be able to discuss a range of novel treatments for PTSD that are currently being tested in clinical trials.

Learning Objective 2: The attendee will be able to identify emerging treatments for PTSD that warrant and/or need additional research.

References

1. Sippel LM, Hamblen JL, Kelmendi B, et al; APA Council of Research Task Force on Novel Biomarkers and Treatments. Novel Pharmacologic and Other Somatic Treatment Approaches for Posttraumatic Stress Disorder in Adults: State of the Evidence. Am J Psychiatry. 2024;181(12):1045-1058. doi: 10.1176/appi.ajp.20230950. PMID: 39616450.
2. Davis LL, Behl S, Lee D, et al. Brexpiprazole and Sertraline Combination Treatment in Posttraumatic Stress Disorder: A Phase 3 Randomized Clinical Trial. JAMA Psychiatry. 2025;82(3):218-227. doi: 10.1001/jamapsychiatry.2024.3996. PMID: 39693081; PMCID: PMC11883513. 3:15 p.m. - 4:45 p.m. Individual Research Reports (IRRs) 1: Psychosis, Sleep, and Learning